Enhanced hemodynamic stability and patient satisfaction with ciprofol-remifentanil versus propofol-remifentanil for sedation in shorter-duration fiberoptic bronchoscopy: a prospective, randomized, double-blind study

作者：Jia Nie, Yongguo Zhang, Yan Wang, Liang Fang, Huanhuan Ma, Yu Zhang, Haiying Wang · 发表于：Frontiers in Medicine · 年份：2025 · DOI：10.3389/fmed.2025.1498010 · 被引用次数：6 · 研究领域：Anesthesia and Sedative Agents、Airway Management and Intubation Techniques、Cancer, Stress, Anesthesia, and Immune Response

Objective This study aimed to compare the efficacy and safety of ciprofol-remifentanil versus propofol-remifentanil in patients undergoing fiberoptic bronchoscopy (FOB). Methods In this prospective, randomized, double-blind, non-inferiority trial, 209 patients undergoing FOB were enrolled and equally divided into two groups ( n = 106 each). The trial was registered in the Chinese Clinical Trial Registry (ChiCTR) under the registration number ChiCTR2400081603. Patients in the ciprofol-remifentanil group received ciprofol at a dose of 0.4 mg/kg, while those in the propofol-remifentanil group received propofol at a dose of 2.5 mg/kg. Both groups were pre-medicated with 1 μg/kg of remifentanil. Anesthesia was maintained with additional doses of the respective anesthetic agent as required to achieve a Modified Observer’s Assessment of Alertness and Sedation (MOAA/S) scale score of ≤1. The primary outcome was the successful completion rate of FOB. Secondary outcomes included hemodynamic stability, incidence of adverse events such as hypoxemia and hypotension, patient and physician satisfaction, and the incidence of pain on injection. Results The successful completion rate of FOB was 92.45% (98 of 106) in the ciprofol-remifentanil group and 90.57% (96 of 106) in the propofol-remifentanil group ( p > 0.05). The ciprofol-remifentanil group demonstrated more stable hemodynamics, with significantly lower incidences of hypotension and hypoxemia compared to the propofol-remifentani...